Products Categories
CAS No.: | 117976-89-3 | |||
---|---|---|---|---|
Name: | Rabeprazole | |||
Article Data: | 43 | |||
Molecular Structure: | ||||
Formula: | C18H21N3O3S | |||
Molecular Weight: | 359.449 | |||
Synonyms: | 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole;1H-benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-;2-({[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole;Pariprazole;(RS)-2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole; | |||
EINECS: | 601-501-2 | |||
Density: | 1.33 g/cm3 | |||
Melting Point: | 202-204°C | |||
Boiling Point: | 603.9 °C at 760 mmHg | |||
Flash Point: | 319.1 °C | |||
Solubility: | Soluble | white to yellowish crystalline powder | ||
Hazard Symbols: | Xi | |||
Risk Codes: | 36/38 | |||
Safety: | 26-37/39 | |||
PSA: | 96.31000 | |||
LogP: | 3.85510 |
2,3-dimethyl-4-(3-methoxy-propoxy)pyridine
(-)-menthyl 2-benzimidazolylsulphinate
rabeprazole
Conditions | Yield |
---|---|
Stage #1: 2,3-dimethyl-4-(3-methoxy-propoxy)pyridine With n-butyllithium In tetrahydrofuran at -90 - -80℃; Stage #2: (-)-menthyl 2-benzimidazolylsulphinate In tetrahydrofuran at -80 - -20℃; | 90% |
rabeprazole sulfide
rabeprazole
Conditions | Yield |
---|---|
With sodium hydroxide; dihydrogen peroxide; sodium tungstate In methanol; water at 20℃; for 0.666667h; Product distribution / selectivity; | 88% |
With dihydrogen peroxide; sodium carbonate; sodium tungstate In methanol; water at 20℃; for 0.666667h; Product distribution / selectivity; | 86.8% |
With sodium hypochlorite; sodium hydroxide In water; acetonitrile Flow reactor; | 85.1% |
Conditions | Yield |
---|---|
With sodium hydroxide; N-chloro-succinimide; water In acetonitrile at 0 - 5℃; for 2h; Product distribution / selectivity; | A 75% B 0.1% |
With 3-chloro-benzenecarboperoxoic acid In dichloromethane at 20℃; for 1h; Product distribution / selectivity; | A 57% B 0.5% |
With sodium hypochlorite; water In dichloromethane at 0 - 5℃; for 3 - 6h; Product distribution / selectivity; | A 52% B 0.5% |
rabeprazole
Conditions | Yield |
---|---|
With methanesulfonyl chloride; N-ethyl-N,N-diisopropylamine In acetonitrile at -10℃; for 6h; Product distribution / selectivity; | 70% |
With methanesulfonyl chloride; N-ethyl-N,N-diisopropylamine In acetonitrile at -10℃; for 6h; Product distribution / selectivity; | 70% |
With methanesulfonyl chloride; triethylamine In dichloromethane at -10℃; Product distribution / selectivity; | |
Stage #1: 2-[4-(3-methoxypropoxy)-3-methyl-1-oxypyridin-2-yl-methylsulfinyl]-1H-benzimidazole sodium salt With methanesulfonyl chloride; triethylamine In dichloromethane at -10℃; Stage #2: With water In dichloromethane Product distribution / selectivity; |
2,3-dimethyl-4-nitropyridine N-oxide
methoxypropanol
Benzimidazol-2-thiol
B
2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide
C
2-[(RS)-[(4-methoxy-3-methylpyridin-2-yl)methyl]sulfinyl]-1H-benzimidazole
D
rabeprazole
Conditions | Yield |
---|---|
Multistep reaction. Further byproducts given; |
2-[[(4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl-1-oxide)methyl]sulfanyl]-1H-benzoimidazole
rabeprazole
Conditions | Yield |
---|---|
With lithium carbonate; ruthenium trichloride; sodium vanadate In acetonitrile for 2h; Heating / reflux; | 5 %Chromat. |
With sodium vanadate; lithium carbonate; ruthenium trichloride In acetonitrile for 2h; Heating / reflux; |
Conditions | Yield |
---|---|
With N-ethyl-N,N-diisopropylamine; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In water; toluene | 1.1 g (49%) |
Conditions | Yield |
---|---|
With N-ethyl-N,N-diisopropylamine; isopropylbenzene hydroperoxide; titanium(IV) isopropylate In water; toluene | 1.36 g (60%) |
Conditions | Yield |
---|---|
Stage #1: 3-chloro-benzenecarboperoxoic acid; rabeprazole sulfide In sodium hydroxide; diethyl ether; dichloromethane at -10℃; for 1.08333h; Stage #2: With triethylamine In diethyl ether; dichloromethane at 0 - 20℃; |
2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide
rabeprazole
Conditions | Yield |
---|---|
Stage #1: 2-[[(RS)-(1H-benzimidazol-2-yl)sulfinyl]methyl]-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide With methanol; sodium methylate; ruthenium trichloride; N,N,N,N,-tetramethylethylenediamine at 50℃; for 10h; Stage #2: With acetic acid; sodium sulfite In water pH=6 - 7; Product distribution / selectivity; |
The Rabeprazole, with the CAS registry number 117976-89-3, has the systematic name of 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole. Its classification code are: Anti-Ulcer Agents; Enzyme Inhibitors; Gastrointestinal Agents. The molecular formula of this chemical is C18H21N3O3S.
The physical properties of Rabeprazole are as following: (1)ACD/LogP: 1.83; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): 1.79; (4)ACD/LogD (pH 7.4): 1.82; (5)ACD/BCF (pH 5.5): 13.1; (6)ACD/BCF (pH 7.4): 14.29; (7)ACD/KOC (pH 5.5): 213.27; (8)ACD/KOC (pH 7.4): 232.59; (9)#H bond acceptors: 6; (10)#H bond donors: 1; (11)#Freely Rotating Bonds: 8; (12)Polar Surface Area: 85.45 Å2; (13)Index of Refraction: 1.654; (14)Molar Refractivity: 98.66 cm3; (15)Molar Volume: 268.9 cm3; (16)Polarizability: 39.11×10-24cm3; (17)Surface Tension: 72.6 dyne/cm; (18)Density: 1.33 g/cm3; (19)Flash Point: 319.1 °C; (20)Enthalpy of Vaporization: 89.82 kJ/mol; (21)Boiling Point: 603.9 °C at 760 mmHg; (22)Vapour Pressure: 1.54E-14 mmHg at 25°C.
Preparation of Rabeprazole: Dissolve 2-[[[3-methyl-4-(3-methoxy-propoxy)-2-pyridyl]methyl]thio]-1H-benzimidazole in the methylene dichloride, and add m-chloroperoxybenzoic acid of dichloromethane. Then deal it with sodium hydroxide, methylene chloride, ammonia and acetone, the aim product is obtained.
Uses of Rabeprazole: It is a proton pump antagonist, and inhibits urease. It is used for the short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD). It is used for maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; It is also used in the treatment of daytime and nighttime heartburn and other symptoms associated with GERD; In addition, it is used for long-term treatment of pathological hypersecretory conditions as well.
You should be cautious while dealing with this chemical. It irritates eyes and skin. Therefore, you had better take the following instructions: Wear suitable gloves and eye/face protection, and in case of contacting with eyes, rinse immediately with plenty of water and seek medical advice.
You can still convert the following datas into molecular structure:
(1)SMILES: O=S(c2nc1ccccc1n2)Cc3nccc(OCCCOC)c3C
(2)InChI: InChI=1/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)
(3)InChIKey: YREYEVIYCVEVJK-UHFFFAOYAY